vs
波士顿科学（MLSS）与MESABI TRUST（MSB）财务数据对比。点击上方公司名可切换其他公司
MESABI TRUST的季度营收约是波士顿科学的1.7倍（$3.6M vs $2.1M），MESABI TRUST净利率更高（77.1% vs -53.0%，领先130.1%），波士顿科学同比增速更快（2.2% vs -95.5%），过去两年波士顿科学的营收复合增速更高（-4.3% vs -24.1%）
波士顿科学公司是源自美国的跨国生物医疗企业，专业研发生产介入医疗领域医疗器械，产品覆盖介入放射学、介入心脏病学、外周介入治疗、神经调控、神经血管介入、电生理、心脏外科、血管外科、内镜、肿瘤学、泌尿与妇科等多个领域。
梅萨比信托是一家总部位于美国的特许权信托机构，持有明尼苏达州梅萨比山脉铁矿开采资产的特许权权益，主要通过与铁矿石生产销售挂钩的特许权使用费获得收益，服务于全球钢铁制造市场。
MLSS vs MSB — 直观对比
营收规模更大
MSB
是对方的1.7倍
$2.1M
营收增速更快
MLSS
高出97.7%
-95.5%
净利率更高
MSB
高出130.1%
-53.0%
两年增速更快
MLSS
近两年复合增速
-24.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.1M | $3.6M |
| 净利润 | $-1.1M | $2.8M |
| 毛利率 | 73.0% | 77.1% |
| 营业利润率 | -52.5% | — |
| 净利率 | -53.0% | 77.1% |
| 营收同比 | 2.2% | -95.5% |
| 净利润同比 | 46.4% | -96.5% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLSSMSB
| Q4 25 | $2.1M | $3.6M | ||
| Q3 25 | $2.4M | $5.6M | ||
| Q2 25 | $2.3M | $4.7M | ||
| Q1 25 | $2.2M | $6.9M | ||
| Q4 24 | $2.0M | $79.0M | ||
| Q3 24 | $2.5M | $6.5M | ||
| Q2 24 | $1.9M | $6.3M | ||
| Q1 24 | $2.2M | $6.2M |
净利润MLSSMSB
| Q4 25 | $-1.1M | $2.8M | ||
| Q3 25 | $-1.2M | $4.7M | ||
| Q2 25 | $-1.5M | $3.6M | ||
| Q1 25 | $-2.0M | $6.1M | ||
| Q4 24 | $-2.0M | $78.3M | ||
| Q3 24 | $-1.5M | $5.4M | ||
| Q2 24 | $223.6K | $3.5M | ||
| Q1 24 | $-1.4M | $4.7M |
毛利率MLSSMSB
| Q4 25 | 73.0% | 77.1% | ||
| Q3 25 | 69.5% | 84.6% | ||
| Q2 25 | 69.6% | 76.7% | ||
| Q1 25 | 73.8% | 88.5% | ||
| Q4 24 | 75.0% | 99.1% | ||
| Q3 24 | 73.0% | 83.2% | ||
| Q2 24 | 76.1% | 55.7% | ||
| Q1 24 | 74.5% | 75.3% |
营业利润率MLSSMSB
| Q4 25 | -52.5% | — | ||
| Q3 25 | -48.1% | — | ||
| Q2 25 | -63.9% | — | ||
| Q1 25 | -89.5% | — | ||
| Q4 24 | -101.4% | — | ||
| Q3 24 | -58.4% | — | ||
| Q2 24 | -96.0% | — | ||
| Q1 24 | -65.1% | — |
净利率MLSSMSB
| Q4 25 | -53.0% | 77.1% | ||
| Q3 25 | -48.9% | 84.6% | ||
| Q2 25 | -63.8% | 76.7% | ||
| Q1 25 | -89.3% | 88.5% | ||
| Q4 24 | -101.1% | 99.1% | ||
| Q3 24 | -58.1% | 83.2% | ||
| Q2 24 | 12.1% | 55.7% | ||
| Q1 24 | -64.1% | 75.3% |
每股收益（稀释后）MLSSMSB
| Q4 25 | — | — | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.8M | $21.1M |
| 总资产 | $7.8M | $26.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MLSSMSB
| Q4 25 | $1.1M | — | ||
| Q3 25 | $1.3M | — | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $4.8M | — | ||
| Q2 24 | $5.8M | — | ||
| Q1 24 | $5.0M | — |
股东权益MLSSMSB
| Q4 25 | $2.8M | $21.1M | ||
| Q3 25 | $2.5M | $22.8M | ||
| Q2 25 | $3.3M | $19.6M | ||
| Q1 25 | $4.5M | $23.3M | ||
| Q4 24 | $5.8M | $95.3M | ||
| Q3 24 | $7.2M | $22.1M | ||
| Q2 24 | $8.0M | $20.7M | ||
| Q1 24 | $7.5M | $21.0M |
总资产MLSSMSB
| Q4 25 | $7.8M | $26.0M | ||
| Q3 25 | $8.5M | $24.8M | ||
| Q2 25 | $8.1M | $27.4M | ||
| Q1 25 | $9.1M | $101.7M | ||
| Q4 24 | $9.8M | $100.7M | ||
| Q3 24 | $11.2M | $26.2M | ||
| Q2 24 | $12.0M | $25.1M | ||
| Q1 24 | $11.4M | $26.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-226.1K | $3.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.27× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MLSSMSB
| Q4 25 | $-226.1K | $3.5M | ||
| Q3 25 | $81.8K | $4.4M | ||
| Q2 25 | $-1.8M | $2.1M | ||
| Q1 25 | $-1.0M | $93.9M | ||
| Q4 24 | $-1.5M | $78.2M | ||
| Q3 24 | $-973.9K | $3.8M | ||
| Q2 24 | $783.7K | $2.5M | ||
| Q1 24 | $-1.2M | $14.6M |
现金转化率MLSSMSB
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 0.92× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 15.48× | ||
| Q4 24 | — | 1.00× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | 3.50× | 0.72× | ||
| Q1 24 | — | 3.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
